Cardinal Health INC

Cardinal Health announced a 6% revenue increase to $63.7 billion for Q4 FY26 and provided FY27 non-GAAP EPS guidance projecting 13-15% growth.

Cardinal Health has entered into a new $4.0 billion unsecured revolving credit agreement, replacing previous facilities and enhancing its financial flexibility.

Cardinal Health announces the appointment of Anita Zielinski as Chief Accounting Officer, effective November 5, 2026, succeeding Mary Scherer.

Cardinal Health reported strong third quarter fiscal year 2026 results, with revenue increasing 11% to $60.9 billion and non-GAAP diluted EPS rising 35% to $3.17, leading the company to raise its full-year outlook.

Cardinal Health announced the retirement of Board Chair Gregory B. Kenny and the appointment of Patricia A. Hemingway Hall, while reaffirming its fiscal 2026 outlook.

Cardinal Health's Senior Vice President and Chief Accounting Officer, Mary Scherer, has announced her intention to retire in February 2027.

Cardinal Health reported an 11% increase in revenue for the third quarter of fiscal year 2026, driven by strong performance in its Pharmaceutical and Specialty Solutions segment.

Cardinal Health announced robust financial results for Q2 fiscal year 2026, with significant revenue and earnings growth fueled by strategic acquisitions and strong performance across its segments.

Cardinal Health reports a robust start to fiscal year 2026 with significant revenue and operating earnings growth, driven by strategic acquisitions and strong pharmaceutical sales.

Cardinal Health's Q3 Fiscal 2025 shows a significant increase in GAAP and non-GAAP operating earnings, driven by pharmaceutical segment growth and strategic acquisitions.

Cardinal Health's second quarter fiscal 2025 results show a revenue decrease due to contract expirations, offset by growth in other areas and strategic acquisitions.

Cardinal Health's first quarter fiscal 2025 results show a revenue decrease of 4% due to the expiration of a major contract, though non-GAAP operating earnings increased by 12%.

Cardinal Health, Inc. announced a 14% revenue increase to $254.2 billion and a 30% rise in non-GAAP operating earnings to $3.6 billion for fiscal year 2026.

Cardinal Health reports significant earnings growth in fiscal 2025, driven by strategic acquisitions and specialty pharmaceutical sales, despite a revenue dip from contract expirations.

Cardinal Health's fiscal year 2024 performance showcased robust revenue growth, driven by increased demand in branded and specialty pharmaceuticals, despite the expiration of key contracts and ongoing industry challenges.

Valerie Christine Pitteroff, Chief Human Resources Officer of Cardinal Health Inc, received 2,610 shares of common stock on August 4, 2026.

Mary C. Scherer, Chief Accounting Officer of Cardinal Health Inc, received 2,610 shares of common stock on August 4, 2026.

Jessica L Mayer, Chief Legal/Compliance Officer of Cardinal Health Inc, received 46,992 shares of common stock on August 4, 2026.

Stephen M Mason, CEO, GMPD Segment of Cardinal Health Inc, received 46,992 shares of common stock on August 4, 2026.

Deborah Weitzman, CEO, PSS Segment of Cardinal Health Inc, received 54,823 shares of common stock on August 4, 2026.

Aaron E Alt, Chief Financial Officer of Cardinal Health Inc, received 58,738 shares of common stock on August 4, 2026.

Cardinal Health, Inc. has filed a Definitive Proxy Statement with the SEC.

Cardinal Health achieved double-digit profit growth across all operating segments in fiscal 2025, driven by strategic acquisitions and operational efficiencies, despite a major contract expiration.

Cardinal Health filed a supplement to its proxy statement to include Inline XBRL tagging and clarify the application of its clawback policy following the correction of an accounting error related to revenue recognition in the at-Home Solutions segment.

Cardinal Health has updated its proxy statement to reflect that director Michelle M. Brennan no longer qualifies as an independent director due to her appointment as interim CEO of Masimo Corporation, a company with which Cardinal Health has a significant commercial relationship.

Cardinal Health has filed a definitive proxy statement with the Securities and Exchange Commission.

Cardinal Health's proxy statement emphasizes a strong fiscal 2024 performance driven by strategic progress and shareholder value creation.

Wellington Management Group LLP and its affiliates have reported a change in their beneficial ownership of Cardinal Health, Inc. common stock, now holding 6.3% of the class.

Vanguard Capital Management has disclosed a beneficial ownership of 7.49% in Cardinal Health Inc., holding over 17.6 million shares.

Vanguard Portfolio Management has reported beneficial ownership of 5.85% of Cardinal Health Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership stake in Cardinal Health Inc. following an internal realignment that disaggregated reporting to its subsidiaries.

BlackRock Portfolio Management LLC has filed an amended Schedule 13G, reporting a 3.8% beneficial ownership stake in Cardinal Health Inc. as of December 31, 2025.

BlackRock Portfolio Management LLC has reported a 5.0% beneficial ownership stake in Cardinal Health Inc., holding 11,947,456 shares of common stock as of September 30, 2025.